Agilent and Imperial College London Strengthen Partnership Agilent Measurement Suite at Imperial to boost research in molecular sciences SANTA CLARA, Calif., March 6, 2019 Agilent Technologies Inc. (NYSE: A) and Imperial College London have announced that, as part of its ongoing collaboration, several state-of-the-art analytical instruments have been installed into the college’s Molecular Sciences Research... Read more
EDEN PRAIRIE, Minn., March 4, 2019 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems, motion simulators and sensors, today announced a research collaboration with the Sismo Lab at Universidad Mariano Gálvez in Guatemala City, Guatemala to create seismic simulation solutions that will help predict and minimize earthquake damage to... Read more
Basel, 28 February 2019 FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast... Read more
Basel, 19 February 2019 FDA grants Priority Review to Roche’s personalised medicine entrectinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor... Read more
Basel, 19 February 2019 FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease Roche (SIX:... Read more
WILSONVILLE, Ore., February 12, 2019 – FLIR Systems, Inc. (NASDAQ: FLIR) today announced the industry’s first high-definition (HD), handheld optical gas imaging (OGI) camera, the FLIR GF620. Designed for oil and gas industry professionals, the GF620 camera sets a new standard for detecting and visualizing invisible leaks of hydrocarbons, such as methane, and common volatile organic... Read more
Basel, 05 February 2019 Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Roche’s application is being reviewed under the US FDA’s Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation... Read more
Dubai, UAE; January 29, 2019: On the sidelines of Arab Health 2019, the region’s leading healthcare exhibition, GE Healthcare and The Aga Khan University Hospital (AKUH) in Karachi, Pakistan, today announced a strategic partnership to give Pakistan’s leading private quaternary care hospital access to a new range of advanced medical imaging and diagnostic equipment. GE... Read more
Shimadzu Corporation has announced plans to build the SHIMADZU Future Collaboratory at the Technology Research Laboratory in Keihanna Science City, Kyoto Prefecture, Japan to expand the program of innovation at Shimadzu Corporation. The new laboratory will further drive research and development by focusing on several core themes including artificial intelligence (AI), innovative biotechnology, brain-science and... Read more
Basel, 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for... Read more